Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Short-Course Fludarabine in Previously Untreated CLL/SLL
NCT02514083Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by National Heart, Lung, and Blood Institute. Started Dec 2015; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02514083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514083.